Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
A phase 3 trial of Neladalkib, Alectinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvalent Inc., now recruiting.
Overview
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC is a phase 3 interventional study registered as NCT06765109 by Nuvalent Inc., with 450 participants planned, started 2025-07-17 and due to reach its primary completion in 2029-12. Interventions recorded: Neladalkib (NVL-655), Alectinib. Conditions listed: Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
Shares Alectinib, Non-small-cell lung cancer.
- TrialALKOVE-1
Shares Neladalkib, Non-small-cell lung cancer.
- TrialA Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C
Shares Alectinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Alectinib, Small-cell lung cancer, Non-small-cell lung cancer.
- CompanyChugai Pharmaceutical
Shares Alectinib, Non-small-cell lung cancer.
- TreatmentZidesamtinib
Shares Nuvalent, Non-small-cell lung cancer.
- TrialA Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Shares Alectinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialALINA
Shares Alectinib, Non-small-cell lung cancer.